Anti-CD19 CAR-T
2018027
Phase 2 mab active
Quick answer
Anti-CD19 CAR-T for Acute Lymphoblastic Leukemia ,Lymphomas is a Phase 2 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Acute Lymphoblastic Leukemia ,Lymphomas
- Phase
- Phase 2
- Modality
- mab
- Status
- active